RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
January 12, 2024
RegMed Investors (RMi) Closing Bell: a Friday’s opening jive followed by afternoon dive after 3-other weekly downfalls
January 11, 2024
RegMed Investors (RMi) Closing Bell: volatility rules
January 10, 2024
RegMed Investors (RMi) Closing Bell: the past curse as clinical and reimbursement risk is on the agenda reassessing 2024 expectations
January 9, 2024
RegMed Investors (RMi) Closing Bell: Volatility is high as selling/profit-taking amplified
January 8, 2024
RegMed Investors (RMi) Closing Bell: news from JPM Healthcare 2024 conference locks-in upside
January 5, 2024
RegMed Investors (RMi) Closing Bell: liquefying the sector from the pre-open thesis
January 4, 2024
RegMed Investors (RMi) Closing Bell: sector turnaround day as some value returns
January 3, 2024
RegMed Investors (RMi) Closing Bell: not feelin’ the love as algorithmic “instructions carry-out a specific order to perform a particular task”
January 2, 2024
RegMed Investors (RMi) Closing Bell: market trips, licensing news juices the cell and gene therapy sector for a while in session
December 29, 2023
RegMed Investors (RMi) Closing Bell: the last session’s hourglass slips empty
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.